Blockchain Registration Transaction Record

NRx Advances Safer Preservative-Free Ketamine Therapies Through Dual FDA Pathways

NRx Pharmaceuticals advances preservative-free ketamine therapies KETAFREE™ and NRX-100 through FDA pathways. Eliminates neurotoxic BZT preservative for safer depression treatment options.

This development matters because it addresses critical safety concerns in ketamine treatments while expanding access to potentially life-saving mental health therapies. The removal of benzethonium chloride (BZT) preservative eliminates a neurotoxic compound from ketamine formulations, reducing patient risk during treatment. For individuals suffering from treatment-resistant depression and suicidal ideation, these preservative-free options could provide safer alternatives to existing ketamine treatments. The dual regulatory approach also demonstrates how pharmaceutical innovation can simultaneously address safety improvements while expanding treatment indications, potentially benefiting millions of patients who struggle with severe depression and bipolar disorder where conventional treatments have failed.